Higher risk of death among MEN1 patients with mutations in the JunD interacting domain: a Groupe d'etude des Tumeurs Endocrines (GTE) cohort study. - Université de Bretagne Occidentale Access content directly
Journal Articles Human Molecular Genetics Year : 2013

Higher risk of death among MEN1 patients with mutations in the JunD interacting domain: a Groupe d'etude des Tumeurs Endocrines (GTE) cohort study.

1 UJF - Université Joseph Fourier - Grenoble 1
2 EA 4271 - Immunovirologie et polymorphisme génétique
3 CIC-EC - Centre d'Investigation Clinique 1432 (Dijon) - Epidemiologie Clinique/Essais Cliniques
4 Centre de génétique - Centre de référence des maladies rares, anomalies du développement et syndromes malformatifs (CHU de Dijon)
5 Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents
6 UNICANCER/CRCL - Centre de Recherche en Cancérologie de Lyon
7 Centre de médecine nucléaire
8 CRN2M - Centre de recherche en neurobiologie - neurophysiologie de Marseille
9 Hôpital Edouard Herriot [CHU - HCL]
10 BORDEAUX - Endocrino - Service d'Endocrinologie
11 Inserm U745 - Genetique et Biotherapies des Maladies Degeneratives et Proliferatives du Systeme Nerveux
12 BCI - Biologie du Cancer et de l'Infection
13 LIEGE - Endocrino - Service d'Endocrinologie
14 Department of Gastroenterology
15 PVM (UMR_7151) - Pathologie et virologie moléculaire
16 Service d'Endocrinologie - Diabète - Nutrition [Reims]
17 LMGE - Laboratoire Microorganismes : Génome et Environnement
18 Centre Hospitalier Universitaire [Rennes]
19 ANGERS - Endocrino - Service d'Endocrinologie
20 Département de Médecine Interne et Nutrition
21 Service Endocrinologie, maladies métaboliques et nutrition [CHU Toulouse]
22 Récepteurs stéroïdiens : physiopathologie endocrinienne et métabolique
23 IGR - Institut Gustave Roussy
24 Médecine nucléaire
25 Service d'Endocrinologie [CHRU Nancy]
26 TOURS - Endocrino - Service d'Endocrinologie
27 Service de Diabétologie - Endocrinologie [CHRU Besançon]
28 PCVP / CARDIO - Marqueurs pronostiques et facteurs de régulations des pathologies cardiaques et vasculaires - UFC ( UR 3920)
29 AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP)
30 Service de Médecine interne B, Endocrinologie, Diabète, Maladies métaboliques [CHU Limoges]
31 GETBO - Groupe d'Etude de la Thrombose de Bretagne Occidentale
32 CHRU - Endocrino - Service d'Endocrinologie
33 Service d'Endocrinologie, Diabétologie et Maladies Métaboliques (CHU de Dijon)
34 Service des maladies métaboliques et endocriniennes
35 NICE - Endocrino - Service d'Endocrinologie
Catherine Cardot-Bauters
  • Function : Author
Arnaud Murat
  • Function : Author
Patricia Niccoli
  • Function : Author
Marie-Françoise Odou
  • Function : Author
Eric Clauser
  • Function : Author
Emilie Castermans
  • Function : Author
Lionel Groussin
  • Function : Author
Hélène Du Boullay
  • Function : Author
Françoise Duron
  • Function : Author
Jean-Marc Kuhn
  • Function : Author
Michel Renard
  • Function : Author
Pierre Goudet
  • Function : Author

Abstract

Multiple endocrine neoplasia syndrome type 1 (MEN1), which is secondary to mutation of the MEN1 gene, is a rare autosomal-dominant disease that predisposes mutation carriers to endocrine tumors. Although genotype-phenotype studies have so far failed to identify any statistical correlations, some families harbor recurrent tumor patterns. The function of MENIN is unclear, but has been described through the discovery of its interacting partners. Mutations in the interacting domains of MENIN functional partners have been shown to directly alter its regulation abilities. We report on a cohort of MEN1 patients from the Groupe d'étude des Tumeurs Endocrines. Patients with a molecular diagnosis and a clinical follow-up, totaling 262 families and 806 patients, were included. Associations between mutation type, location or interacting factors of the MENIN protein and death as well as the occurrence of MEN1-related tumors were tested using a frailty Cox model to adjust for potential heterogeneity across families. Accounting for the heterogeneity across families, the overall risk of death was significantly higher when mutations affected the JunD interacting domain (adjusted HR = 1.88: 95%-CI = 1.15-3.07). Patients had a higher risk of death from cancers of the MEN1 spectrum (HR = 2.34; 95%-CI = 1.23-4.43). This genotype-phenotype correlation study confirmed the lack of direct genotype-phenotype correlations. However, patients with mutations affecting the JunD interacting domain had a higher risk of death secondary to a MEN1 tumor and should thus be considered for surgical indications, genetic counseling and follow-up.

Dates and versions

hal-00935869 , version 1 (24-01-2014)

Identifiers

Cite

Julien Thevenon, Abderrahmane Bourredjem, Laurence Faivre, Catherine Cardot-Bauters, Alain Calender, et al.. Higher risk of death among MEN1 patients with mutations in the JunD interacting domain: a Groupe d'etude des Tumeurs Endocrines (GTE) cohort study.. Human Molecular Genetics, 2013, 22 (10), pp.1940-8. ⟨10.1093/hmg/ddt039⟩. ⟨hal-00935869⟩
689 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More